Mississippi Medicaid spending on GLP-1 drugs

How much did Mississippi Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $70.7 million for GLP-1 drugs paid through Mississippi Medicaid in 2025, across at least 61,646 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 115 rows of 285, so these figures are floors.

Pharmacies were reimbursed at least $20.8 million for GLP-1 drugs paid through Mississippi Medicaid in 2026 (quarter 1 only, as posted so far), across at least 17,804 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 28 rows of 76, so these figures are floors.

By year and ingredient

2020at least $377,012No data$5,791,474at least $484,818at least $2,645,740SuppressedSuppressedat least $9,299,044
2021at least $836,356No dataat least $8,646,493at least $698,794at least $676,428SuppressedSuppressedat least $10,858,071
2022at least $1,902,256at least $17,446at least $11,566,691at least $946,352at least $577,761at least $21,205Suppressedat least $15,031,710
2023at least $4,151,468at least $835,530at least $10,399,421at least $11,664,427at least $306,168at least $22,212Suppressedat least $27,379,227
2024at least $20,486,714at least $1,644,294at least $3,780,195at least $16,751,090at least $168,514at least $19,765Suppressedat least $42,850,572
2025at least $44,602,364at least $2,568,945at least $1,436,862at least $22,079,090at least $31,460SuppressedSuppressedat least $70,718,721
2026 (Q1)at least $13,956,038at least $996,501at least $331,837$5,501,562No dataNo dataNo dataat least $20,785,939

By product, 2025

Ozempicat least $2,489,998at least 2,4917 of 27
Rybelsusat least $126,642at least 12912 of 19
Wegovyat least $41,985,725at least 31,7851 of 41
Mounjaroat least $2,384,183at least 2,25715 of 44
Zepboundat least $184,762at least 17422 of 28
Liraglutide (generic name listing)at least $170,082at least 30029 of 42
Saxendaat least $322,239at least 2753 of 8
Victoza$944,5411,4760 of 16
Trulicityat least $22,079,090at least 22,72110 of 42
BydureonSuppressedSuppressed3 of 3
Byettaat least $31,460at least 386 of 8
Exenatide (generic name listing)SuppressedSuppressed3 of 3
SoliquaSuppressedSuppressed2 of 2
XultophySuppressedSuppressed2 of 2

By quarter, 2025

Q1 2025at least $14,534,719at least 12,99523 of 62
Q2 2025at least $17,172,655at least 14,99231 of 72
Q3 2025at least $18,728,235at least 16,24632 of 76
Q4 2025at least $20,283,111at least 17,41329 of 75

By quarter, 2026 (posted so far)

Q1 2026at least $20,785,939at least 17,80428 of 76

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.